We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+4.51%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$791M
AUM Growth
-$79M
Cap. Flow
-$79.2M
Cap. Flow %
-10.01%
Top 10 Hldgs %
32.88%
Holding
105
New
11
Increased
29
Reduced
37
Closed
15

Top Buys

Rank Stock Value
1
DHR icon
Danaher
DHR
+$15.4M
2
LLY icon
Eli Lilly
LLY
+$12.5M
3
EHC icon
Encompass Health
EHC
+$11.3M
4
CAH icon
Cardinal Health
CAH
+$8.16M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$6.81M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$19.8M
2
UNH icon
UnitedHealth
UNH
+$18M
3
PRCT icon
Procept Biorobotics
PRCT
+$14.6M
4
MOH icon
Molina Healthcare
MOH
+$14.4M
5
MCK icon
McKesson
MCK
+$13.8M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COO icon
26
Cooper Companies
COO
$14.5B
$12.1M 1.53%
170,000
-66,000
-28% -$5.05M
JAZZ icon
27
Jazz Pharmaceuticals
JAZZ
$16.7B
$11.6M 1.46%
109,030
-15,270
-12% -$1.66M
HCA icon
28
HCA Healthcare
HCA
$89.5B
$11.4M 1.44%
29,778
+13,000
+77% +$4.68M
PRCT icon
29
Procept Biorobotics
PRCT
$1.17B
$10.9M 1.38%
190,000
-258,000
-58% -$14.6M
CI icon
30
Cigna
CI
$74.6B
$10.6M 1.34%
32,000
+3,800
+13% +$1.22M
AKRO
31
DELISTED
Akero Therapeutics
AKRO
$10.5M 1.33%
197,600
+105,100
+114% +$4.78M
VRNA
32
DELISTED
Verona Pharma
VRNA
$10.1M 1.27%
106,500
+36,500
+52% +$2.7M
NTRA icon
33
Natera
NTRA
$46.4B
$9.71M 1.23%
57,500
-81,000
-58% -$12.6M
UNH icon
34
UnitedHealth
UNH
$370B
$9.49M 1.2%
30,430
-47,000
-61% -$18M
AXSM icon
35
Axsome Therapeutics
AXSM
$10.9B
$9.48M 1.2%
90,800
-18,800
-17% -$1.99M
CAH icon
36
Cardinal Health
CAH
$55.4B
$9.24M 1.17%
+55,000
New +$8.16M
BMRN icon
37
BioMarin Pharmaceuticals
BMRN
$12.4B
$8.23M 1.04%
149,650
-115,350
-44% -$6.79M
ABT icon
38
Abbott
ABT
$187B
$7.96M 1.01%
58,500
+6,500
+13% +$857K
IONS icon
39
Ionis Pharmaceuticals
IONS
$9.4B
$7.19M 0.91%
182,000
+101,000
+125% +$3.31M
OSCR icon
40
Oscar Health
OSCR
$8.61B
$6.69M 0.85%
312,092
-710,651
-69% -$10.6M
MOH icon
41
Molina Healthcare
MOH
$10.3B
$6.61M 0.84%
22,200
-46,000
-67% -$14.4M
MRUS
42
DELISTED
Merus
MRUS
$6.1M 0.77%
116,000
+41,500
+56% +$1.95M
ALC icon
43
Alcon
ALC
$35B
$5.99M 0.76%
+68,000
New +$6.1M
DVAX
44
DELISTED
Dynavax Technologies
DVAX
$5.6M 0.71%
565,000
– –
PEN icon
45
Penumbra
PEN
$12.8B
$5.52M 0.7%
21,500
+19,300
+877% +$5.25M
CNC icon
46
Centene
CNC
$32.5B
$5.41M 0.68%
99,757
-26,243
-21% -$1.54M
SNDX icon
47
Syndax Pharmaceuticals
SNDX
$1.82B
$5.38M 0.68%
574,000
+141,000
+33% +$1.55M
BRKR icon
48
Bruker
BRKR
$8.14B
$5.08M 0.64%
123,315
+81,000
+191% +$3.13M
AVR
49
Anteris Technologies
AVR
$867M
$4.74M 0.6%
1,250,763
-39,237
-3% -$160K
ASTH icon
50
Astrana Health
ASTH
$1.77B
$4.73M 0.6%
190,000
+40,000
+27% +$1.13M
1
2
3 4 5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2025 Portfolio in Review

As of Q2 2025, Rhenman & Partners Asset Management held 105 positions worth $791M, down 9.1% from $870M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $79.2M in Q2 2025, closing 15 positions and reducing 37 holdings. Its most notable exit was Bristol-Myers Squibb, an estimated $19.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Rhenman & Partners Asset Management opened a new position in Cardinal Health worth $9.24M.

  • Rhenman & Partners Asset Management's largest Q2 2025 buy was Cardinal Health: 55,000 shares worth $9.24M.
  • Rhenman & Partners Asset Management added most to Danaher in Q2 2025, an estimated $15.4M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2025 reduction was UnitedHealth, cutting an estimated $18M.
  • Rhenman & Partners Asset Management fully exited Bristol-Myers Squibb in Q2 2025, selling an estimated $19.8M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 33% of its $791M portfolio in Q2 2025.
  • Rhenman & Partners Asset Management opened 11 new positions and closed 15 in Q2 2025.
  • Rhenman & Partners Asset Management's portfolio value fell 9.1% quarter-over-quarter to $791M.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2025, filed 13 Aug 2025.